Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study
dc.contributor.author | Rini, Brian I. | |
dc.contributor.author | Halabi, Susan | |
dc.contributor.author | Barrier, Robert | |
dc.contributor.author | Margolin, Kim A. | |
dc.contributor.author | Avigan, David | |
dc.contributor.author | Logan, Theodore | |
dc.contributor.author | Stadler, Walter M. | |
dc.contributor.author | McCarthy, Philip L. | |
dc.contributor.author | Linker, Charles A. | |
dc.contributor.author | Small, Eric J. | |
dc.contributor.department | Medicine, School of Medicine | en_US |
dc.date.accessioned | 2022-12-08T22:40:14Z | |
dc.date.available | 2022-12-08T22:40:14Z | |
dc.date.issued | 2006-07-01 | |
dc.description.abstract | A graft-versus-tumor effect through nonmyeloablative allogeneic stem cell transplantation (N-SCT) in metastatic renal cell carcinoma (RCC) has been reported. An Intergroup phase II trial was undertaken to define further the feasibility, toxicity and efficacy of this approach in a multi-institutional setting, Patients with cytokine-refractory, metastatic RCC were treated with N-SCT. The conditioning regimen was fludarabine 30 mg · m−2 · d−1 on day (d) −7 through d −3 and cyclophosphamide 60 mg · kg−1 · d−1 on d −4 and d −3. Patients received 2-8 × 106 CD34+ cells/kg of granulocyte colony-stimulating factor mobilized stem cells from a 6/6 HLA-matched sibling donor. Immunosuppression after transplantation included tacrolimus and methotrexate. Twenty-two patients were enrolled at 14 institutions. Greater than 90% donor T-cell chimerism was observed in 17 of 19 evaluable patients (89%) by d +120. No objective response was observed. Acute graft-versus-host disease (GVHD) was observed in 11 patients (50%). Chronic GVHD was reported in 5 patients (23%). There was 1 patient death from liver failure secondary to chronic GVHD. Regimen-related mortality was 2 of 22 (9%; liver failure, sepsis). Median survival time was 5.5 months (95% confidence interval, 3.9-12.0 months) and the median time to progression was 3.0 months (95% confidence interval, 2.3-4.2 months). N-SCT for metastatic RCC is feasible in a multi-institutional setting. Adequate donor T-cell engraftment was achieved in most patients before disease progression. A graft-versus-tumor effect was not observed in this study despite acute and chronic GVHD, thus highlighting the need for further understanding of this approach. Allogeneic SCT remains investigational in RCC. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Rini, B. I., Halabi, S., Barrier, R., Margolin, K. A., Avigan, D., Logan, T., Stadler, W. M., McCarthy, P. L., Linker, C. A., & Small, E. J. (2006). Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study. Biology of Blood and Marrow Transplantation, 12(7), 778–785. https://doi.org/10.1016/j.bbmt.2006.03.011 | en_US |
dc.identifier.issn | 1523-6536 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/30695 | |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.isversionof | 10.1016/j.bbmt.2006.03.011 | en_US |
dc.relation.journal | Biology of Blood and Marrow Transplantation | en_US |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | * |
dc.source | Publisher | en_US |
dc.subject | Allogeneic | en_US |
dc.subject | Nonmyeloablative transplant | en_US |
dc.subject | Renal cell carcinoma | en_US |
dc.title | Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study | en_US |
dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Rini2006Adoptive-CCBYNCND.pdf
- Size:
- 133.38 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.99 KB
- Format:
- Item-specific license agreed upon to submission
- Description: